Argos Therapeutics Inc., a Durham, N.C.-based immunotherapy company focused on cancer, has sold the rights to an experimental lupus therapy to Novo Nordisk for up to $69 million. Argos has raised around $60 million in VC funding from firms like The Aurora Funds, ABN Amro, Intersouth Partners, Cordova Ventures, TVM Capital, MDS Health Ventures, CDP Capital and Oakwood Medical Investors. Argos, formerly known as Merix Bioscience, participated in the SEBIO Investor Forums in 1999 and 2001. www.argostherapeutics.com